Photo from wikipedia
Percutaneous treatments of valvular heart disease have evolved over the past two decades. These “minimally invasive” procedures are attractive alternatives to surgery for a growing high-risk population with multiple comorbidities.… Click to show full abstract
Percutaneous treatments of valvular heart disease have evolved over the past two decades. These “minimally invasive” procedures are attractive alternatives to surgery for a growing high-risk population with multiple comorbidities. In 2002, Cribier et al. (1) performed the first transcatheter aortic valve implantation (TAVI) in a patient with aortic stenosis. Currently, TAVI has become a common procedure for high or prohibitive surgical risk patient and is moving rapidly into intermediate risk patients, with over 250,000 devices implanted worldwide.
Journal Title: Journal of thoracic disease
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!